Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate
(Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia,
including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being
observed for any bone adverse events or other serious adverse events, as well as the
collection of mortality data.